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IL-12 and IL-23 Affect Photocarcinogenesis
Differently
Christian Jantschitsch1,2, Michael Weichenthal1, Ehrhardt Proksch1, Thomas Schwarz1 and Agatha Schwarz1
Induction of DNA damage by UVR is the key event in photocarcinogenesis. IL-12 and IL-23 are related
heterodimeric cytokines consisting of a common p40 unit and a p35/IL-12 and a p19/IL-23 chain, respectively.
Both exert immunomodulatory activities but are also found to reduce UVR-induced DNA damage presumably
via induction of DNA repair. As both cytokines are also produced in the skin, they may mitigate the risk to
develop UVR-induced skin cancer. This appears to be the case as mice lacking p40 were previously shown to
be at higher risk for skin tumors upon chronic UVR exposure. As these mice express neither IL-12 nor IL-23,
the individual effects of IL-12 or IL-23 could not be evaluated. Thus, mice lacking p35 (IL-12p35/) or p19
(IL-23p19/) were subjected to chronic UVR exposure. The Kaplan–Meier analysis indicated a significantly
increased probability of tumor development in IL-23p19/ but not in IL-12p35/ mice. Taken together, in our
model, loss of IL-23, but not of IL-12, enhances development of UVR-induced skin tumors, indicating that IL-23
but not IL-12 may counteract photocarcinogenesis. This may have impact on the development of future
strategies utilizing antibodies against IL-12 and IL-23, respectively, for the treatment of inflammatory dermatoses.
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INTRODUCTION
Solar UVR, in particular the mid-wave range (UVB,
290–320 nm), is the predominant causal factor for skin cancer
(de Grujil, 1999). The key event in photocarcinogenesis is
the induction of DNA damage. Even low, suberythemogenic
UVB doses induce DNA lesions, mostly cyclobutane
pyrimidine dimers (CPDs) and (6-4) photoproducts (Patrick,
1977). The vast majority of photolesions is efficiently
removed by the nucleotide excision repair (NER) (de Laat
et al., 1999). Hence, defects in the NER, as impressively
demonstrated by the disease xeroderma pigmentosum,
dramatically increase the risk for skin cancer (Kraemer
et al., 1994). In turn, accelerated or enhanced reduction of
DNA damage, as principally proven by the use of exogenous
DNA repair enzymes, reduces the photocarcinogenic risk
(Yarosh et al., 2001). Hence, lowering the load of DNA
damage either by modulating the NER or by other mechan-
isms is an essential component of recent sun protection
strategies (Verschooten et al., 2006).
IL-12 is a heterodimeric cytokine consisting of a p35 and
a p40 chain. Because of its immunomodulatory activities it
is a major player in orchestrating both innate and acquired
immune responses (Trinchieri, 1998). One of its major
features among many others is its crucial role in the develop-
ment of T helper 1 responses. In addition, IL-12 exerts the
capacity to reduce the amounts of UVR-induced DNA damage
(Schwarz et al., 2002). This activity appears to be mediated via
the NER as the effect is not observed in NER-deficient mice
and cells. This was a very surprising observation as it was the
first discovery that the NER can be modulated by cytokines.
For quite a long time IL-12 is known to prevent UVR-induced
immunosuppression (Mu¨ller et al., 1995; Schmitt et al., 1995;
Schwarz et al., 1996). This effect appears to be related to its
capacity to reduce UVR-induced DNA damage (Schwarz
et al., 2005), which is the major molecular mediator in
photoimmunosuppression (Kripke et al., 1992).
IL-23 was described several years after the discovery of
IL-12. It is closely related to IL-12 as it shares the same
p40 unit that associates with a p19 chain (Hunter, 2005).
Accordingly, IL-23 shares some biological activities with
IL-12, but it also exerts different biological effects (Kastelein
et al., 2007). These have been mainly linked to a T helper 17
cell response (Mills, 2008). Recently, we observed that IL-23
exerts similar effects on UVR-induced damage as IL-12
(Majewski et al., 2010). IL-23 reduces the amounts of CPDs
both in vitro and in vivo. Studies utilizing Xpa knockout
mice indicated that this effect involves the NER. Accordingly,
IL-23 prevents the suppression of the induction of contact
hypersensitivity by UVR (Majewski et al., 2010). Taken
together, IL-23 appears to exert similar effects on UVR-
induced DNA damage as IL-12.
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Since the discovery that IL-12 can reduce UVR-induced
DNA damage, speculations exist whether IL-12 prevents
photocarcinogenesis through this capacity (Schwarz et al.,
2002). This assumption was supported by the fact that IL-12
can be produced in the skin (Aragane et al., 1994; Mu¨ller
et al., 1994). Consequently, photocarcinogenesis studies
utilizing p40 knockout mice were performed and revealed
in fact a higher risk of developing skin cancer when
compared with chronically UVR exposed wild-type (WT)
mice (Maeda et al., 2006). Hence, it was concluded that
IL-12 exerts a mitigating effect on photocarcinogenesis.
However, this conclusion has to be re-examined because,
as we know today, p40 knockout mice are deficient in not
only IL-12 but also IL-23. To examine whether IL-12 and
IL-23 exert similar effects on the induction of UVR-mediated
skin cancer or differ in this respect, photocarcinogenesis
studies were performed with p35 and p19 knockout mice.
Only p19-deficient mice revealed a higher probability of
developing skin tumors but not p35-deficient mice. The risk
of p19-deficient mice was lower when compared with the
previous results with p40 knockout mice. This implies that
loss of IL-12 seems to be compensated by IL-23, but not vice
versa, explaining the slightly enhanced carcinogenesis risk in
the absence of IL-23. Loss of both, however, further enhances
the risk of UVR-induced skin cancer.
RESULTS
Enhanced photocarcinogenesis in mice lacking IL-23
To address the influence of IL-12 and IL-23 on photo-
carcinogenesis, mice lacking p35 (IL-12p35/) or p19
(IL-23p19/) and WT mice (C57BL/6) were exposed to a
chronic UVB regimen known to induce skin tumors after
B200 days (Beissert et al., 2001; Maeda et al., 2006).
Unirradiated mice of each group served as controls.
Beginning with the first exposures to UVR the entire
observation period covered 80 weeks. The Kaplan–Meier
analysis revealed that IL-12p35/ as well as IL-23p19/
mice developed UVR-induced skin tumors faster than WT
mice (Figure 1a and b). However, this effect was statistically
significant only in IL-23p19/ animals. In none of the
control mice, development of a spontaneous skin tumor was
observed.
Higher rate of non-epithelial malignant tumors in mice lacking
IL-23 or IL-12
Tumors were excised when their volume exceeded 1 cm3
or when they became necrotic. Paraffin sections were
stained with hematoxylin and eosin and sections analyzed
in a blinded fashion (Supplementary Figure S1 online). As
expected, the majority of UVR-induced malignancies in WT
mice were of epithelial origin (64%), either squamous cell
carcinomas (SCCs, 52%) or basal cell carcinomas (12%;
Figure 2 and Table 1a). In contrast, malignant tumors from
IL-23p19/ and IL-12p35/ mice were predominantly
sarcomas. This phenomenon was more pronounced in
IL-23p19/ (77% sarcomas) than in IL-12p35/ animals
(64% sarcomas; Figure 2 and Table 1a).
As demonstrated in Table 1a, the total number of tumors
induced in IL-23p19/ animals was remarkably lower than
in WT or IL-12p35/ mice. On the first glance, this may be
contradictory to the data shown in Figure 1, but because of
the fact that the tumors grew substantially faster than those
in WT or IL-12p35/ mice, IL-23p19/ mice had to be
killed much earlier before additional tumors could develop.
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Figure 1. Kaplan–Meier analysis of tumors induced by UVR. Mice were exposed thrice weekly for the first 4 weeks with 2.5 kJm–2, for the next 4 weeks
with 5 kJm–2, and finally for 16 weeks with 10 kJm–2 of UVB (UVR wild type (WT), UVR IL-23p19/, and UVR IL-12p35/). Controls were untreated mice
of each mouse strain used (WT, IL-23p19/, and IL-12p35/). The probability of tumor development was estimated according to Kaplan–Meier analysis.
The graph depicts probabilities of tumor development for each of the treatment groups, with ticks indicating censored observations, i.e., mice
dying without tumor development before the end of the observation time. Each group consisted of 22 mice. (a) Probability of tumor development in
IL-23p19/ versus WT mice. (b) Probability of tumor development in IL-12p35/ versus WT mice. The data for the WT mice are identical in a and b.
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Figure 2. Distribution of UVR-induced epithelial and non-epithelial
malignant tumors. Percent of epithelial (black; squamous cell carcinomas
(SCCs) and basal cell carcinomas (BCCs)) and non-epithelial (white;
sarcomas) malignant tumors in wild-type (WT), IL-23p19/, and
IL-12p35/ mice.
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In the IL-23p19/ group, 71% of tumor-bearing animals
had to be killed because of the tumor volume above 1 cm3 or
excessive necrosis/ulceration. In contrast, in the IL-12p35/
group the rate was 52%, and in the WT group it was only
18%. In addition, some of the IL-23p19/ mice died
prematurely without tumor development, thus contributing to
the lower total number of tumors in this group.
Anatomic distribution of tumors
The majority of tumors developed on the back (Table 1b).
When stratified by tumor type, it turned out that SCCs and
basal cell carcinomas preferentially developed on the
ears, whereas sarcomas were observed mainly on the back
(Table 1c). On the ears, where 77.3% of SCCs but only 3% of
sarcomas developed (Table 1c), the number of tumors was
substantially lower in both IL-12p35/ and IL-23p19/
mice in comparison with WT mice (Table 1a and b).
Non-epithelial tumors develop significantly earlier in
IL-23p19/ mice
Separate Kaplan–Meier analysis for UVR-induced epithelial
(SCCs and basal cell carcinomas) and non-epithelial malig-
nant tumors revealed that occurrence of epithelial malig-
nant tumors was accelerated neither in IL-12p35/ nor in
IL-23p19/ mice (Figure 3a and b). In contrast, non-epithe-
lial malignant skin tumors (sarcomas) developed significantly
earlier in IL-23p19/ than in WT animals (Figure 3c and d).
Higher proliferative capacity of malignant tumors in mice
lacking IL-12 or IL-23
As soon as UVR-induced tumors had developed, their volume
was recorded at least once weekly and the average growth
rate in mm3 per week was calculated from the pooled tumors
of each group. There was a trend of increased growth of
tumors in IL-12p35/ and IL-23p19/ animals compared
with WT mice (Figure 4a). This was mostly because of the
growth behavior of non-epithelial malignant tumors (sarco-
mas; Figure 4b), whereas lack of IL-12 or IL-23 did not
influence the growth rate of epithelial tumors (Figure 4c).
These results were confirmed by evaluating the expression
of Ki-67. Immunohistochemical stainings were evaluated in
a blinded fashion and tumors classified as low (0–10%),
medium (11–30%), and high (430%) Ki-67-positive cells.
The fraction of high Ki-67-positive (¼highly proliferating)
tumors was higher in IL-12p35/ and IL-23p19/ animals
than in WT mice (Figure 4d). This difference was much
more pronounced when sarcomas were analyzed separately
(data not shown).
To study the in vitro growth behavior, cell lines were
established from SCCs and sarcomas and cultivated. As in the
IL-23p19/ group only a single SCC developed (Table 1a),
the in vitro proliferation rate was analyzed for non-epithelial
malignant tumors (sarcomas) only. A total of 16 sarcoma
cell lines were subjected to 3-(4,5-dimthylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) proliferation assays,
which were performed immediately (0 hours) and 72 hours
Table 1a. Histological diagnoses of tumors induced
by UVR
Tumor types IL-12p35/ IL-23p19/ Wild type
Malignant tumors
Squamous cell carcinomas 8 (36.4%) 1 (7.8%) 13 (52%)
Basal cell carcinomas 0 2 (15.4%) 3 (12%)
Sarcomas 14 (63.6%) 10 (76.9%) 9 (36%)
Total 22 (100%) 13 (100%) 25 (100%)
Benign tumors
Papillomas 0 1 (100%) 4 (100%)
Dermatofibromas 4 (80%) 0 0
Trichoepitheliomas 1 (20%) 0 0
Total 5 (100%) 1 (100%) 4 (100%)
Table 1c. Correlation of tumor types with anatomic location
Anatomic location SCC BCC Sarcoma Papilloma Dermatofibroma Trichoepithelioma
Ear 17 (77.3%) 3 (60%) 1 (3%) 0 0 1 (100%)
Back 4 (18.2%) 1 (20%) 26 (78.8%) 5 (100%) 4 (100%) 0
Eye 1 (4.5%) 0 6 (18.2%) 0 0 0
Face 0 1 (20%) 0 0 0 0
Total 22 (100%) 5 (100%) 33 (100%) 5 (100%) 4 (100%) 1 (100%)
Abbreviations: BBC, basal cell carcinoma; SCC, squamous cell carcinoma.
Table 1b. Anatomic location of tumors induced by
UVR
Anatomic location IL-12p35/ IL-23p19/ Wild type
Ear 7 (25.9%) 3 (21.4%) 12 (41.4%)
Back 15 (55.6%) 10 (71.4%) 15 (51.7%)
Eye 5 (18.5%) 1 (7.1%) 1 (3.4%)
Face 0 0 1 (3.4%)
Total 27 (100%) 14 (100%) 29 (100%)
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after seeding. The absorption values at 0 hours were set
as 1 and the increase of proliferation after 72 hours was
calculated. Cell lines derived from sarcomas occurring either
in IL-12p35/ (7 cell lines) or in IL-23p19/ (6 cell lines)
revealed a slightly increased proliferation rate. The differ-
ences, however, were not significant when compared with
the proliferation of tumor cell lines generated from WT mice
(3 cell lines; Figure 4e). This correlated with the findings
obtained in the colony formation assays. Both the numbers
and sizes of colonies were higher in cell lines derived from
either IL-12p35/ or IL-23/p19/ mice in comparison
with tumor cells obtained from WT mice (Figure 4f).
DISCUSSION
The discovery that IL-12 exerts the capacity to reduce UVR-
induced DNA damage via modulating the NER was quite
surprising and unexpected, as it was assumed that the NER as
a kind of emergency system is not subjected to any regulation
and not susceptible to external influences. Soon thereafter, it
was reported that this activity is not confined to IL-12
but applies also to other mediators, including IL-18 and
a-melanocyte-stimulating hormone (Bo¨hm et al., 2005; Schwarz
et al., 2006). Because of the structural similarities, IL-23 shares
some of the biological activities with IL-12. Hence, it was not
surprising that IL-23 exerts similar effects on UVR-induced DNA
damage (Majewski et al., 2010). As UVR-induced DNA
damage is the major molecular mediator of UVR-induced
immunosuppression (Kripke et al., 1992), it was predicted
that any cytokine that reduces DNA lesions should prevent
UVR-induced immunosuppression. This in fact applies for
IL-12 and IL-23; injection of either cytokine prevents the
UVR-mediated suppression of sensitization (Schwarz et al.,
1996; Majewski et al., 2010).
Additional speculations about the biological relevance
of these unique features of IL-12 and IL-23 extended to
carcinogenesis. Both cytokines can be produced in the skin
(Aragane et al., 1994; Mu¨ller et al., 1994; Takenaka et al.,
2011). Hence, one could surmise that a constant release of
IL-12 or IL-23 could reduce the risk of photocarcinogenesis
by reducing UVR-induced DNA damage. Accordingly, this
question was addressed by utilizing p40 knockout mice. They
revealed a significantly enhanced risk of developing skin
tumors upon chronic UVR exposure (Maeda et al., 2006).
These findings were interpreted that IL-12 can in fact reduce
photocarcinogenesis. The option that IL-23 might as well
contribute in this system was not considered. Shortly there-
after, p35 knockout mice were found to be more prone to
skin cancer upon chronic UVR exposure in comparison with
WT mice (Meeran et al., 2006). This study also indicated
a link to NER. Basically, this paper studied the effect of
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Figure 3. Kaplan–Meier analysis of epithelial tumors and sarcomas induced by UVR. Data displayed in Figure 1 were reanalyzed and the probability of
developing epithelial malignant tumors (a, b) and sarcomas calculated separately (c, d). The graph depicts probabilities of tumor development for each
of the treatment groups, with ticks indicating censored observations, i.e., mice dying without tumor development before the end of the observation time.
Panels a and c show the data for IL-23p19/ versus WT mice, and b and d for IL-12p35/ versus WT mice. The data for the WT mice are identical in a and b
and c and d, respectively.
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epigallocatechin-3-gallate (EGCG) on skin cancer. The
authors showed that EGCG reduced the frequency of UVR-
induced skin cancer. This effect was not observed in p35
knockout mice, indicating that EGCG acts via IL-12, which
was confirmed shortly thereafter by other studies (Schwarz
et al., 2008). In addition, reduction of CPDs by EGCG was
not only reduced in p35 knockout mice but also in Xpa
knockout mice, suggesting that EGCG acts via IL-12 that
ultimately modulates the NER, finally resulting in reduction of
CPDs (Meeran et al., 2006).
As neither of these studies allows to differentiate the effects
of IL-12 or IL-23 on photocarcinogenesis independently, this
study was performed comparing IL-23p19/ versus
IL-12p35/ mice. The Kaplan–Meier analysis indicated that
both knockout strains revealed a higher risk of developing
skin tumors when compared with WT mice. However, in
IL-12p35/ mice, this trend was minimally pronounced
and statistically not significant. All mice that made it to the
end of the observation period developed tumors. We selected
Kaplan–Meier estimates for calculating the probability of
tumor development. This kind of analysis makes maximum
use of the information by keeping all animals in the analysis.
Our findings obtained with the IL-12p35/ mice are in
contrast to the findings by Meeran et al. (2006) who did see
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Figure 4. Proliferation of UVR-induced malignant tumors in vivo and in vitro. Tumor volumes were recorded at least once weekly and the average growth
rate in mm3 per week was calculated. UVR-induced malignant tumors were pooled according to the mouse strain in which they developed (wild type
(WT), IL-23p19/, and IL-12p35/). (a) The volumes of all tumors, (b) and of non-epithelial and (c) epithelial tumors are shown. Error bars depict SD.
NS, not significant versus WT, *P¼ 0.032 versus WT. (d) Immunohistochemistry of malignant tumor samples was carried out using an antibody against
Ki-67. The fraction of proliferating cells, resembling Ki-67-positive cells in the tumor, was estimated. The frequency of 0–10% Ki-67-positive cells was defined
as low (white), 11–30% as medium (med, gray) and over 30% as high (black) proliferative capacity. (e) Cells were obtained from 16 surgically removed
sarcomas of WT (3 tumors), IL-23p19/ (7 tumors), and IL-12p35/ (6 tumors) mice. Proliferation was measured using 3-(4,5-dimthylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) proliferation assay immediately (0 hours) and 72hours after onset of culture. The values at 0 hours were set as 1 and
the increase of proliferation after 72 hours was calculated. For each tumor cell line, MTT assays were at least performed twice independently. Data are
expressed as mean±SEM. NS versus WT. (f) To determine the colony-forming efficiency, tumor cell lines (sarcomas) were seeded at low concentrations
into Petri dishes and the outgrowth of colonies was analyzed after 14 days by visualizing the colonies with crystal violet. One representative of four
independently performed experiments is shown.
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an increased risk. The reason for these differences remains to
be determined but may be because of the different mouse
strains used (C3H/HeN vs. C57BL/6) or because of different
irradiation protocols. Retrospective comparison of the data
obtained with the IL-23p19/ mice with the previously
published findings observed in p40/ mice (Maeda et al.,
2006) revealed that p40/ mice apparently are at a higher
risk of developing skin cancer. Although a retrospective
juxtaposition of data has limitations, it appears possible that
the loss of either IL12 or IL-23 can be at least partially
compensated by the fellow cytokine. Nevertheless, IL-23
seems to play a more dominant role in protecting from
photocarcinogenesis than IL-12. Loss of both cytokines,
however, appears to have the maximum impact as shown
in the p40/ mice (Maeda et al., 2006).
Another striking feature of this study is the shift in the types
of tumors induced by UVR in the absence of IL-12 or IL-23.
In WT mice, the vast majority were epithelial carcinomas.
Surprisingly, this ratio was shifted in favor of sarcomas in the
knockout mice. In addition, the more aggressive growth
behavior of the tumors in the knockout mice and the
increased proliferation rate of cell lines established from
these tumors were mostly because of the sarcomas. The
increased frequency of sarcomas upon chronic UVR expo-
sure was surprising and similar findings are not reported in
the literature. However, one has to be aware that careful
histological analysis including histochemical characteriza-
tion in most of these studies was not performed. Hence, it
would be interesting to study retrospectively whether those
tumors described as dedifferentiated carcinomas were in fact
exclusively carcinomas or whether sarcomas were also
among those neoplasms. Accordingly, we tried to reanalyze
samples of the previous study (Maeda et al., 2006). Although
we did not have access to all samples, we were able to obtain
23 tumors that could be allocated to either p40/ or WT
mice. After a careful reanalysis in a blinded fashion by our
pathologist, 56% of the tumors obtained from p40/ mice
had to be reclassified as sarcomas. In contrast, no sarcoma
was found in the WT group. Hence, it appears that the vast
majority of tumors described as dedifferentiated carcinomas
in our previous paper were in fact sarcomas. Although limited
by the fact that we could not reanalyze all tumors of the
previous study, the percentage of sarcomas in the p40/
group is in the same range as in this study.
Whether the observed sarcomas are truly of dermal origin
or the product of epithelial–mesenchymal transition cannot
be deducted from our data. It has been described that EGF
and transforming growth factor-b may induce epithelial–
mesenchymal transition in breast cancer (Ackland et al.,
2003; Wendt et al., 2010). The fact that sarcomas developed
preferentially on the back and not on the ears gives rise to the
speculation that topographic differences in the structure of
the skin may be of relevance. This may include the fact that
the dermis of the ears is much thinner and consequently
much fewer fibroblasts per surface area exposed to UVR.
In case of epithelial–mesenchymal transition being the driving
force, different environmental conditions on the back and on
the ears might influence this process as well. As the rate of
sarcomas was substantially increased in the absence of IL-12
or IL-23, these cytokines might directly or indirectly inhibit
epithelial–mesenchymal transition. With regard to carcino-
mas in murine skin, it has been shown that IL-23 promotes
tumor formation via favoring a proinflammatory environment
and reducing the amount of infiltrating CD8þ cytotoxic
T cells (Langowski et al., 2006). The authors demonstrated
that depletion of IL-23 inhibited tumor growth of transplanted
carcinomas. Their data are in accordance with ours as we
also observed a decreased rate of carcinomas in IL-23p19/
mice.
IL-12 and IL-23 can be expressed in human skin (Mu¨ller
et al., 1994; Yawalkar et al., 2009). In addition, the reducing
effect of IL-12 on CPDs has been confirmed in human cells
(Schwarz et al., 2002). Whether this applies for IL-23 also
remains to be determined, but in our view is highly likely.
IL-12 and IL-23 are attractive candidates for immune inter-
vention. Antibodies blocking the p40 unit are approved for
the therapy of psoriasis and have turned out to be highly
effective (Papp et al., 2008). Initially, IL-12 was the primary
target cytokine, but with time it turned out that IL-23 may be
even more important in the pathogenesis of psoriasis, as
increased p19 mRNA but not p35 mRNA was found in
lesional skin compared with nonlesional skin of patients with
psoriasis (Lee et al., 2004). Hence, antibodies blocking the
p19 unit are developed and will be tested in clinical studies
soon. Ustekinumab, which blocks p40, is well tolerated. The
most frequent side effects include microbial infections.
Whether long-term therapy with ustekinumab increases the
risk of skin cancer can only be answered by long-term follow-
up studies. As IL-12 and IL-23 appear to affect the NER, the
question is obvious of whether blocking either of these cyto-
kines increases the amounts of UVR-induced DNA damage
and in the long term enhances the risk of skin cancer. The
primary targets of the anti-IL-12 therapy are definitely
T lymphocytes and not keratinocytes. It is unclear whether
relevant amounts of these antibodies that are administered
systemically reach the skin except the area of injection.
Hence, it is thoroughly possible that these antibodies acting
in a systemic fashion do not affect keratinocytes and fibro-
blasts, respectively. Nevertheless, this could be easily
clarified by comparing the amounts of CPDs in biopsies of
UVR-exposed skin before and during antibody therapy.
Unless such studies have been performed, consequent UVR
protection is recommended for patients undergoing therapy
with biologics that target either IL-12 or IL-23. In addition,
combination with phototherapy has to be discouraged.
MATERIALS AND METHODS
Mice
Female C57BL/6J mice were purchased from Charles River
Laboratories (Sulzfeld, Germany). Female IL12atm1Jm/J mice were
obtained from Jackson Laboratories (Bar Harbor, ME) via Charles
River Laboratories. These mice (C57BL/6J background) lack the p35
chain of IL-12 and hence do not produce functional IL-12 (Mattner
et al., 1996). Female IL23a mice (C57BL/6J background) were
obtained from Genentech (San Francisco, CA). IL23a mice (C57BL/6J
background) lack the p19 chain of IL-23 and therefore have no
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functional IL-23 (Ghilardi et al., 2004). All mice were 8 weeks of age
when the irradiation protocol was started. Animal care was provided
by expert personnel in compliance with the relevant laws and
institutional guidelines.
Irradiation and tumor induction
UVR exposures were performed using a bank of Philips TL12
fluorescent lamps (Philips, Eindhoven, The Netherlands), which emit
most of their energy within the UVB range (290–320 nm) with an
emission peak at 313 nm. Mice were placed 20 cm below the light
bulbs for irradiation. The mice (22 in each group) were shaved with
electric clippers on the entire dorsum once weekly. Mice were
irradiated thrice weekly for the first 4 weeks with 2.5 kJm–2, for the
next 4 weeks with 5 kJm–2, and finally for 16 weeks with 10 kJ/m–2
(cumulative dose: 570 kJm–2). Untreated mice of each strain served
as controls. Tumor development was monitored twice weekly during
the irradiation period and thereafter for 56 weeks. The location and
growth of each tumor exceeding 2mm in diameter were recorded
and photographically documented. The average growth rate in mm3
per week was calculated from all tumors pooled of each group. Mice
were killed by cervical dislocation when the volume of a tumor
exceeded 1 cm3 or the tumor was necrotic. Tumors were removed
surgically and one part was fixed in 4% formalin and embedded in
paraffin; the other part was used to establish tumor cell lines
(see below). Sections were stained with hematoxylin and eosin and
were diagnosed in a blinded fashion by a veterinary pathologist
(Dr Frantisek Jelinek, AnLab, Prague, Czech Republic), a dermato-
pathologist (EP), and a pathologist specialized in soft tissue tumors
(Professor Ivo Leuschner, Institute for Pathology, University Clinics
of Schleswig-Holstein, Kiel, Germany). For evaluation of the degree
of proliferative activity, sections were stained with an antibody
directed against Ki-67 (clone SP6, Neomarker via Thermo Fisher
Scientific, Fremont, CA) using a standard immunoperoxidase
technique. The amount of Ki-67-positive cells was estimated in a
blinded fashion and tumors were classified as low (0–10%), medium
(11–30%), and highly positive (431% Ki-67 positive cells).
Establishment of tumor cell lines
Tumors were surgically removed and rinsed twice with phosphate-
buffered saline supplemented with 1% antibiotic/antimycotic solu-
tion (PAA Laboratories, Linz, Austria). Small pieces (o2mm3) were
seeded in 25 cm2 cell culture flasks containing RPMI-1640
supplemented with 20% fetal calf serum, 1% glutamine and 1%
nonessential amino acids, and 1% HEPES buffer solution (all from
PAA Laboratories). All cells were maintained at 37 1C in a humidified
atmosphere containing 5% CO2. When the cultures had reached
B80% confluence, the adherent cells were detached with 0.1%
trypsin/0.05% EDTA (PAA Laboratories) and used for subsequent
passage. A total of 28 tumors were utilized to establish tumor cell
lines. In all, 22 tumor cell lines could be established, which
corresponds to a 79% success rate. The outgrowth rate was higher in
sarcomas (84%) than in epithelial tumors (67%).
Proliferation assay
The proliferative capacity of tumor cell lines was assessed using the
tetrazolium salt (MTT) proliferation assay (Sigma-Aldrich, St Louis,
MO). The MTT method involves the conversion of MTT to colored
formazan by cells and serves as an indirect measurement of cell
growth. Tumor cells were seeded in triplicates into 96-well plates at
a density of 2.5 103 cells per well. At 0 hours and 72 hours after
seeding, MTT solution (25 ml; 5mgml–1 in phosphate-buffered saline)
was added to each well followed by incubation at 37 1C. After
4 hours, SDS-formamide buffer was added to dissolve the dark
formazan crystals (10% SDS, 50% formamide, pH 4.7, 100 ml per
well). After overnight incubation at 37 1C, spectrophotometric
absorbance of each sample was measured at 595 nm using a
microplate reader (Bio-Rad, Hercules, CA). The values at 0 hours
were set as 1 and the increase of proliferation after 72 hours was
calculated. The mean values of the MTT assays of 16 different
sarcoma lines (7 lines from IL-23p19/ mice, 6 from IL-12p35/
mice, and 3 from WT mice) were determined in 32 independent
experiments (each cell line was tested at least twice).
To determine the colony-forming efficiency, the tumor cell lines
were seeded at low concentrations (350 cells cm–2) into 6 cm Petri
dishes. The outgrowth of colonies was analyzed 14 days after
seeding by visualizing the colonies with crystal violet.
Statistical analysis
The method of Kaplan and Meier was used to describe the
probability of development of a malignant tumor (tumor-free
survival) in the carcinogenesis study (Figures 1 and 3). This is a
life-table analysis and takes into account animals that die before
developing a malignant tumor. The differences in tumor latent
periods were analyzed by the log-rank test. The differences in
Figure 4d (proportions of highly proliferating tumors) were analyzed
using w2 test. All other differences were analyzed using Student’s
t-test. Differences were considered significant at Po0.05.
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